In the past week, CDMO stock has gone up by 0.24%, with a monthly gain of 1.22% and a quarterly surge of 22.66%. The volatility ratio for the week is 0.39%, and the volatility levels for the last 30 days are 0.42% for Avid Bioservices Inc The simple moving average for the past 20 days is 0.77% for CDMO’s stock, with a 24.96% simple moving average for the past 200 days.
Is It Worth Investing in Avid Bioservices Inc (NASDAQ: CDMO) Right Now?
The 36-month beta value for CDMO is at 1.39. Analysts have varying views on the stock, with 1 analysts rating it as a “buy,” 0 rating it as “overweight,” 4 as “hold,” and 0 as “sell.”
The public float for CDMO is 63.08M, and currently, shorts hold a 17.75% of that float. The average trading volume for CDMO on January 23, 2025 was 2.07M shares.
CDMO) stock’s latest price update
The stock price of Avid Bioservices Inc (NASDAQ: CDMO) has plunged by -0.08 when compared to previous closing price of 12.46, but the company has seen a 0.24% gain in its stock price over the last five trading sessions. globenewswire.com reported 2025-01-22 that Mails Letter to Stockholders Highlighting the Significant, Immediate and Certain Cash Value the Transaction Delivers to Stockholders Mails Letter to Stockholders Highlighting the Significant, Immediate and Certain Cash Value the Transaction Delivers to Stockholders
Analysts’ Opinion of CDMO
KeyBanc Capital Markets, on the other hand, stated in their research note that they expect to see CDMO reach a price target of $20. The rating they have provided for CDMO stocks is “Overweight” according to the report published on March 14th, 2023.
CDMO Trading at 1.21% from the 50-Day Moving Average
After a stumble in the market that brought CDMO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -0.24% of loss for the given period.
Volatility was left at 0.42%, however, over the last 30 days, the volatility rate increased by 0.39%, as shares surge +0.97% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +13.39% upper at present.
During the last 5 trading sessions, CDMO rose by +0.24%, which changed the moving average for the period of 200-days by +96.37% in comparison to the 20-day moving average, which settled at $12.36. In addition, Avid Bioservices Inc saw 0.81% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CDMO starting from Richieri Richard A., who sale 2,283 shares at the price of $12.37 back on Jan 10 ’25. After this action, Richieri Richard A. now owns 49,535 shares of Avid Bioservices Inc, valued at $28,241 using the latest closing price.
Richieri Richard A., the Chief Operations Officer of Avid Bioservices Inc, sale 200 shares at $12.37 during a trade that took place back on Jan 10 ’25, which means that Richieri Richard A. is holding 8,785 shares at $2,474 based on the most recent closing price.
Stock Fundamentals for CDMO
Current profitability levels for the company are sitting at:
- -0.14 for the present operating margin
- 0.08 for the gross margin
The net margin for Avid Bioservices Inc stands at -1.01. The total capital return value is set at -0.08. Equity return is now at value -133.29, with -39.04 for asset returns.
Based on Avid Bioservices Inc (CDMO), the company’s capital structure generated 0.82 points at debt to capital in total, while cash flow to debt ratio is standing at -0.02. The debt to equity ratio resting at 4.59. The interest coverage ratio of the stock is -2.42.
Currently, EBITDA for the company is -11.48 million with net debt to EBITDA at -12.18. When we switch over and look at the enterprise to sales, we see a ratio of 6.44. The receivables turnover for the company is 4.98for trailing twelve months and the total asset turnover is 0.47. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.30.
Conclusion
In conclusion, Avid Bioservices Inc (CDMO) has had a better performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
